



## **Quest Diagnostics to Speak at Wachovia Securities Cancer Diagnostics Conference**

February 23, 2004

TETERBORO, N.J., Feb. 23 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that Joyce G. Schwartz, M.D., Vice President and Chief Laboratory Officer, and Richard A. Bender, M.D., Medical Director, Hematology/Oncology, are scheduled to speak at the Wachovia Securities Cancer Diagnostics Conference on Tuesday, February 24, 2004, at The New York Palace Hotel, in New York City. The Quest Diagnostics presentation is scheduled to begin at 8:00 a.m. Eastern Time.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: <http://www.wallstreetwebcasting.com/webcast/fu19/dgx/> and to the public on <http://www.questdiagnostics.com>. In addition, the archived webcast will be available starting approximately three hours after the live presentation and will be available for 60 days.

Quest Diagnostics Incorporated is the nation's leading provider of diagnostic testing, information and services, providing insights that enable physicians, hospitals, managed care organizations and other healthcare professionals to make decisions to improve health. The company offers the broadest access to diagnostic laboratory services through its national network of laboratories and patient service centers. Quest Diagnostics is the leading provider of esoteric testing, including gene-based medical testing, and empowers healthcare organizations and clinicians with advanced information technology solutions that improve practice management. Additional company information can be found on the Internet at: <http://www.questdiagnostics.com>.

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results and outcomes to be materially different. Certain of these risks and uncertainties may include, but are not limited to, unanticipated expenditures, changing relationships with customers, payers, suppliers and strategic partners, competitive environment, changes in government regulations, conditions of the economy, integration of acquired businesses, and other factors described in the filings of Quest Diagnostics Incorporated with the Securities & Exchange Commission, including its 2002 Form 10-K.

SOURCE Quest Diagnostics Incorporated -0- 02/23/2004 /CONTACT: Investors: Laure Park, +1-201-393-5030, Media: Gary Samuels, +1-201-393-5700 /Web site: <http://www.questdiagnostics.com> / (DGX) CO: Quest Diagnostics Incorporated ST: New Jersey